Atrys Health increases its revenues 59% to 4.56 million euros
March 14, 2017
Madrid, March 14, 2017.- Atrys Health, S.A., a company dedicated to the provision of diagnostic services and medical treatments of excellence, has presented an advance of the audited figures of its results for the 2016 financial year.
The company obtained revenues of 4.56 million euros, an increase of 59.4% over 2015 and a gross margin of 3.04 million euros, improving the gross margin obtained by 71.6% in 2015.
In 2016, ATRYS achieved EBITDA of 1.05 million euros (97.6% increase over 2015) and increased its recurring EBITDA (adjusted for outgoing expenses to the MAB) by 149.2% to 1 , 33 million euros.
The company closed the 2016 financial year with a net profit of 63 thousand euros.
In the words of ATRYS 'CEO, Santiago de Torres, "Thanks to the effort and commitment of the entire ATRYS professional team, as well as to the trust of our customers, we have achieved the goals we had set ourselves and progressively improving, business areas."
Regarding the behavior of the different business areas:
51% of the income generated by the company corresponds to the area of personalized cancer diagnosis, which shows a positive behavior, with a revenue growth in 2016 of 74% compared to 2015.
This significant increase is due to the impulse that the company has achieved in this area with the contracting of services by the health systems of several autonomous communities, the incorporation of new services in the field of clinical trials of pharmaceutical companies and activities Of pathological anatomy for large health groups.
38% of the revenues correspond to the area of online image diagnosis, which in 2016 increases by 23% compared to the previous year.
The company has focused its commercial efforts in the first half of the year on boosting the activity of teleradiology in Spain, which is reflected in the evolution of its revenues, with a growing trend month by month during 2016, Year with more than ninety thousand diagnostic tests reported by the team of radiologists at ATRYS.
The advanced radiotherapy oncology business area, which began operations in February 2016, represents 11% of total revenues in 2016. Lastly, in 2016, the company launched several R & D lines aimed at strengthening the portfolio of products and services, highlighting the development of diagnostic tests based on liquid biopsy.
Following its OPS in July to the Alternative Stock Market, and reinforced by the results obtained in 2016, ATRYS maintains its commitment to continue boosting its revenues in all its business areas in Spain and other international markets.
About Atrys Health:
ATRYS is an innovative company dedicated to the provision of diagnostic services and medical treatments of excellence, combining precision diagnostic techniques in pathological and molecular anatomy and online diagnostic imaging, through its own multi-specialty technology platform, with new Oncological radiotherapy treatments.
ATRYS performs an integrated management of oncological disease, from individualized diagnosis (anatomic pathological, molecular, genetic and radiological), to treatment of hypo-fractured or single dose radiotherapy, through collaboration agreements with health centers of reference. The company also offers on-line diagnostic medical imaging services in different specialties, through its own platform, such as radiology, cardiology, ophthalmology and dermatology.
These services allow you to relocate the report of the specialist of the center in which the test is performed. ATRYS also develops applied R & D projects that have generated several patent families, in collaboration with national and international reference centers, aimed at improving diagnostic systems and treatment modalities, allowing the Company to incorporate the latest Scientific advances to their clinical practice. The company, based in Madrid, has two main laboratories, equipped with the most advanced equipment and technologies for diagnosis and research, located in Barcelona and the Genyo Center in Granada.
For more information see: Relevant Fact Preview Results Atrys Health 2016